238 related articles for article (PubMed ID: 21149672)
1. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
2. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
3. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
4. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
[TBL] [Abstract][Full Text] [Related]
5. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
Miyata A; Yasuda Y; Fujii S; Kikuchi T
Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
[TBL] [Abstract][Full Text] [Related]
6. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
[TBL] [Abstract][Full Text] [Related]
7. Successful immunosuppressive therapy for a child with Myelodysplastic syndrome.
Orimoto M; Maeda M; Cai LZ; Hayakawa J; Ueda T; Migita M; Asano T
Med Pediatr Oncol; 2003 May; 40(5):334-5. PubMed ID: 12652627
[No Abstract] [Full Text] [Related]
8. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
9. [Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome].
Kokhno AV; Parovichnikova EN; Mikhaĭlova EA; Ustinova EN; Kaplanskaia IB; Dvirnyk VN; Ol'shanskaia IuV; Domracheva EV; Savchenko VG
Ter Arkh; 2010; 82(8):48-53. PubMed ID: 20873246
[TBL] [Abstract][Full Text] [Related]
10. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.
Arber C; Buser A; Heim D; Gratwohl A; Tichelli A; Passweg JR
Eur J Haematol; 2006 Mar; 76(3):255-7. PubMed ID: 16451398
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
[TBL] [Abstract][Full Text] [Related]
13. [Sequential intensified immunosuppressive therapy combining with hematopoietic growth factors in the treatment of severe aplastic anemia].
He G; Shao Z; Zhang Y; Liu H; Li K; Song L; Zheng Y; Chen G; He H; Zhao M; Shi J; Zhang H; Chu Y; Qian L; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Apr; 22(4):177-81. PubMed ID: 11877068
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
15. [Antilymphocyte globulin combining with cyclosporine A in the treatment of severe aplastic anemia].
Zheng Y; Chu Y; Shao Z
Zhonghua Xue Ye Xue Za Zhi; 1999 Apr; 20(4):175-7. PubMed ID: 11601221
[TBL] [Abstract][Full Text] [Related]
16. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
[TBL] [Abstract][Full Text] [Related]
17. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
Molldrem JJ; Leifer E; Bahceci E; Saunthararajah Y; Rivera M; Dunbar C; Liu J; Nakamura R; Young NS; Barrett AJ
Ann Intern Med; 2002 Aug; 137(3):156-63. PubMed ID: 12160363
[TBL] [Abstract][Full Text] [Related]
18. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolonged marrow failure after hemophagocytic syndrome.
Kaito K; Otsubo H; Takei Y; Usui N; Kobayashi M
Ann Hematol; 2003 Nov; 82(11):699-701. PubMed ID: 12961029
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome.
Biesma DH; van den Tweel JG; Verdonck LF
Cancer; 1997 Apr; 79(8):1548-51. PubMed ID: 9118037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
